Table 2.
Ongoing phase 3 clinical trials of anti-angiogenic therapy with or without anti-PD-1/PD-L1 antibody for advanced or unresectable hepatocellular carcinoma.
| Trial | Lines | Arms | Clinicaltrials.gov identifier | Sponsor |
|---|---|---|---|---|
| ZGDH3 | First line | donafenib vs sorafenib | NCT02645981 | Zelgen |
| LEAP-002 | First line | lenvatinib + pembrolizumab vs lenvatinib | NCT03713593 | MSD + Eisai |
| COSMIC-312 | First line | cabozantinib + atezolizumab vs sorafenib vs cabozantinib | NCT03755791 | Exelixis |
| SHR-1210-III-310 | First line | camrelizumab + apatinib vs sorafenib | NCT03764293 | Hengrui |
| ORIENT-32 | First line | sintilimab + IBI305 vs sorafenib | NCT03794440 | Innovent |